Advice
following a full submission
peginterferon-beta-1a (Plegridy®) is accepted for use within NHS Scotland.
Indication under review: in adult patients for the treatment of relapsing remitting multiple sclerosis.
Peginterferon-beta-1a, compared with placebo, improved annualised relapse rate in adults with relapsing remitting multiple sclerosis.
Download detailed advice183KB (PDF)
Medicine details
- Medicine name:
- peginterferon beta 1a (Plegridy)
- SMC ID:
- 1018/14
- Indication:
- In adult patients for the treatment of relapsing remitting multiple sclerosis.
- Pharmaceutical company
- Biogen Idec Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 January 2015